Earlier this year, we published an overview of federal lobbying efforts related to psychedelics, based on filings by organisations like advocacy groups, other nonprofits and drug developers.

Of course, these figures don’t entirely capture efforts to lobby members of the federal government—and its numerous committees and agencies—to support psychedelic research, drug development, and related policy reforms; and they don’t capture the work going on at the state and local level, or the international level.

Nonetheless, they do offer something of an insight into the efforts these groups are making to create a more favourable environment for the ultimate roll-out of psychedelics in the medical field, or outside of the medical model entirely.

Here, we provide an update based on recent filings that show lobbying activity in the third quarter of 2024 (Q3’24)…